Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.

Abstract

The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis.

• Authors: Sven A Silfverdal, Deepak Assudani, Sherine Kuriyakose, Olivier Van Der Meeren
• Journal: Human vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 10 Issue 10 Pg. 2795-8 ( 2014) ISSN: 2164-554X [Electronic] United States
• PMID: 25483640 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Bacterial
• Diphtheria-Tetanus-Pertussis Vaccine
• Haemophilus Vaccines
• Hepatitis B Antibodies
• Hepatitis B Vaccines
• Poliovirus Vaccine, Inactivated
• Vaccines, Combined
• diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Topics

• Antibodies, Bacterial (blood, immunology)
• Antibody Formation
• Bordetella pertussis (immunology)
• Child, Preschool
• Clostridium tetani (immunology)
• Corynebacterium diphtheriae (immunology)
• Diphtheria (immunology, prevention & control)
• Diphtheria-Tetanus-Pertussis Vaccine (immunology)
• Haemophilus Infections (immunology, prevention & control)
• Haemophilus Vaccines (immunology)
• Haemophilus influenzae type b (immunology)
• Hepatitis B (immunology, prevention & control)
• Hepatitis B Antibodies (blood)
• Hepatitis B Vaccines (immunology)
• Humans
• Immunization Schedule
• Immunization, Secondary
• Poliomyelitis (immunology, prevention & control)
• Poliovirus Vaccine, Inactivated (immunology)
• Tetanus (immunology, prevention & control)
• Vaccination
• Vaccines, Combined (immunology)
• Whooping Cough (immunology, prevention & control)